Cogstate
ASX:CGS Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
WA
Consensus Narrative from 1 Analyst
Reacquisition Of Eisai IP Will Unlock New Markets For Clinical Trials
Key Takeaways Diversification into new indications and reacquisition of IP expand market opportunities, enhance revenue potential, and reduce dependency on single areas. Strategic focus on Alzheimer's R&D and operational efficiencies drive future revenue growth, improved margins, and a robust contract pipeline.
View narrativeAU$1.45
FV
3.4% undervalued intrinsic discount11.28%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
11 days ago author updated this narrative